Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  3. CNTA

(CNTA)

0.00

0.00 (0.00%)

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Centessa Pharmaceuticals plc

CountryUnited Kingdom
IndustryBiotechnology
SectorHealthcare
IPO Date2021-05-28
CEOMario Accardi

About the company

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key Executives

NamePosition
Dr. Gregory M. Weinhoff M.B.A., M.D.Chief Business Officer
Dr. Mario Alberto Accardi Ph.D.CEO & Director
Dr. Stephen J. Kanes M.D., Ph.D.Head of R&D and Chief Medical Officer
Mr. Iqbal J. Hussain L.L.B.Chief Legal Officer, Chief Compliance Officer & Company Secretary
Mr. John J. Crowley CPACFO & Principal Financial Officer
Mr. Raphael Deferiere CPAChief Accounting Officer & Principal Accounting Officer
Ms. Charlene StoudtSenior Vice President of Clinical Development Operations

Centessa Pharmaceuticals plc

CountryUnited Kingdom
IndustryBiotechnology
SectorHealthcare
IPO Date2021-05-28
CEOMario Accardi

Contact Details

Address:1 Ashley Road, 3rd Floor, Altrincham, WA14 2DT, United Kingdom
Phone:N/A
Website:https://centessa.com

Stock Details

Latest SEC Filings

DateTypeDocument
2026-01-078-K/Ad51805d8ka.htm
2025-12-118-Kd933269d8k.htm
2025-11-0510-Qcnta-20250930.htm
2025-08-128-Kcnta-20250812.htm
2025-06-208-Kcnta-20250620.htm
2025-06-178-Kcnta-20250616.htm
2025-05-298-Kcnta-20250527.htm
2025-05-28DEFA14Acntsa-defa14a.htm
2025-05-1410-Qcnta-20250331.htm
2025-05-06ARScentessa_ars-123124.pdf
Ms. Karen M. AndersonChief People Officer
Ms. Kristen K. Sheppard Esq., J.D.Senior Vice President of Investor Relations & Corporate Communications
Ms. Tia L. BushChief Technology & Quality Officer
Ticker Symbol:CNTA
Exchange:NASDAQ
Fiscal Year:January - December
Reporting Currency:USD
CIK Code:1847903
CUSIP Number:152309100
ISIN Number:US1523091007
SIC Code:2834